Sugi Predict

Sugi Predict / Compounds / SCHEMBL443655

SCHEMBL443655

SCHEMBL443655

COC(=O)C1CCN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.47
▸ NR1H2 P55055 1/20 0.46
▸ NR1H3 Q13133 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ FKBP1A P62942 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ LMNA P02545 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ EPHX1 P07099 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ SCN4A P35499 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ UCHL1 P09936 1/20 0.40
▸ USP30 Q70CQ3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995875 1.00 HSD17B10 (0.47) HSD17B10NR1H2NR1H3PTPN1FKBP1A
SCHEMBL26353928 1.00 HSD17B10 (0.47) HSD17B10NR1H2NR1H3PTPN1FKBP1A
SCHEMBL190042 0.90 HSD17B10 (0.58) HSD17B10FKBP1ASMN1; SMN2NPC1LMNA
SCHEMBL883030 0.90 HSD17B10 (0.58) HSD17B10FKBP1ASMN1; SMN2NPC1LMNA
SCHEMBL1486184 0.90 HSD17B10 (0.58) HSD17B10FKBP1ASMN1; SMN2NPC1LMNA
SCHEMBL7328713 0.89 HSD17B10 (0.49) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL18555624 0.89 NR1H2 (0.42) HSD17B10NR1H2NR1H3PTPN1FKBP1A
SCHEMBL18555530 0.89 NR1H2 (0.42) HSD17B10NR1H2NR1H3PTPN1FKBP1A
SCHEMBL26136953 0.89 NR1H2 (0.42) HSD17B10NR1H2NR1H3PTPN1FKBP1A
SCHEMBL88684 0.89 FKBP1A (0.58) HSD17B10FKBP1ASMN1; SMN2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111582-A1 AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D GENENTECH, INC. (US) 2025-05-30 — — WO disclosed
WO-2025051148-A1 NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技股份有限公司 2025-03-13 — — WO disclosed
US-20250042919-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2025-02-06 — — US disclosed
CN-119320383-A Nitrogen-containing heteroaryl compound, and preparation method and application thereof 北京鞍石生物科技股份有限公司 2025-01-17 — — CN disclosed
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2024-11-21 — — US disclosed
CN-113412113-B Amino oxazinamides 豪夫迈·罗氏有限公司 2024-07-26 — — CN disclosed
EP-4320132-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-02-14 — — EP disclosed
EP-4291563-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2023-12-20 — — EP disclosed
CN-117083279-A Oxazepine compounds and their use in the treatment of cancer 基因泰克公司 2023-11-17 — — CN disclosed
WO-2023215801-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-11-09 — — WO disclosed
US-20030124683-A1 Enzyme preparation and method of using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-07-03 — — US disclosed
EP-1316610-A1 Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-04 — — EP disclosed
US-6537790-B1 Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-03-25 — — US disclosed
US-20020173013-A1 Esterace genes and uses of the same SUMITOMO CHEMICAL COMPANY, LIMITED 2002-11-21 — — US disclosed
US-20020164727-A1 Nucleotide sequences coding polypeptide for use as tool in genetic engineering SUMITOMO CHEMICAL COMPANY, LIMITED 2002-11-07 — — US disclosed
EP-1201653-A1 Method for racemization of optically active azetidine-2-Carboxylate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-05-02 — — EP disclosed
US-6166224-A Method for racemization of optically active azetidine-2-carboxylate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-12-26 — — US disclosed
EP-1057894-A2 Esterase genes and uses of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-12-06 — — EP disclosed
EP-0957089-A1 Method for racemization of optically active azetidine-2-carboxylate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-11-17 — — EP disclosed
US-5409946-A Antiepileptic agent ABBOTT LABORATORIES (US) 1995-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020164727-A1 Nucleotide sequences coding polypeptide for use as tool in genetic engineering IMPDH2, INHA, IMPDH1 HSD17B10 592/4885NR1H2 4676/4885NR1H3 4612/4885
US-20020173013-A1 Esterace genes and uses of the same ACOT7, COASY, IMPA1 HSD17B10 11/4885NR1H2 3069/4885NR1H3 3495/4885
US-20250042919-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF OXA1L, CACNA1I, GRIK5 HSD17B10 1219/4885NR1H2 724/4885NR1H3 667/4885
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER OXA1L, GRIK4, GRIK5 HSD17B10 447/4885NR1H2 702/4885NR1H3 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.